Technology Appraisal Guidance No. 330
Source: National Institute for Health and Care Excellence
1.1 Sofosbuvir is recommended as an option for treating chronic hepatitis C in adults, as specified in table below.
Sofosbuvir for treating adults with chronic hepatitis C
|Sofosbuvir in combination with peginterferon alfa and ribavirin||Sofosbuvir in combination with ribavirin|
|Genotype||Treatment history||Recommendation||Treatment history||Recommendation|
|Adults with genotype 1 HCV||All||Recommended||All||Not recommended|
|Adults with genotype 2 HCV
||All||Not licensed for this population||Treatment-naive||Only recommended for people who are intolerant to or ineligible for interferon|
|Adults with genotype 3 HCV||Treatment-naive||Only recommended for people with cirrhosis||Treatment-naive||Only recommended for people with cirrhosis who are intolerant to or ineligible for interferon|
|Treatment-experienced||Recommended||Treatment-experienced||Only recommended for people with cirrhosis who are intolerant to or ineligible for interferon|
|Adults with genotype 4, 5 or 6 HCV||All||Only recommended for people with cirrhosis||All||Not recommended|
HCV - hepatitis C virus
Treatment-naive – the person has not had treatment for chronic hepatitis C
Treatment-experienced – the person's hepatitis C has not adequately responded to interferon-based treatment
1.2 People currently receiving treatment initiated within the NHS with sofosbuvir that is not recommended for them by NICE in this guidance should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.
The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at http://guidance.nice.org.uk/TA330
This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.
© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.
Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email: firstname.lastname@example.org
Sofosbuvir for treating chronic hepatitis C.
Issue Date: February 2015